04.29.16
Alexion
1Q Revenues: $701 million (+17%)
1Q Earnings: $92.2 million (+1%)
Comments: Soliris saw steady increase of new patients in the U.S., Europe and Japan with sales of $665 million, up 17%. Strensiq for Hypophosphatasia launched with $33 million sales in initial countries. U.S. launch for Kanuma (sebelipase alfa) for Lysosomal Acid Lipase (LAL) deficiency is under way.
1Q Revenues: $701 million (+17%)
1Q Earnings: $92.2 million (+1%)
Comments: Soliris saw steady increase of new patients in the U.S., Europe and Japan with sales of $665 million, up 17%. Strensiq for Hypophosphatasia launched with $33 million sales in initial countries. U.S. launch for Kanuma (sebelipase alfa) for Lysosomal Acid Lipase (LAL) deficiency is under way.
